Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

(English title: Physiological Journal)

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2026; 72(4): 81-92

THE ROLE OF MITOCHONDRIAL DYSFUNCTION IN THE DEVELOPMENT OF PARKINSON`S DISEASE

R.V. Rozova1, D.S. Krasnenkov2, I.M. Karaban2

  1. O.O. Bogomolets Institute of Physiology, NAS of Ukraine, Kyiv, Ukraine
  2. D.F. Chebotaryov Institute of Gerontology, NAMS of Ukraine, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz72.04.081


Abstract

A significant part of neurodegenerative disorders may be attributed to so-called mitochondrial diseases. Parkinson’s disease (PD), one of the most common neurodegenerative pathologies after Alzheimer’s disease, is among those disorders that may be linked to mitochondrial dysfunction. The relationship between PD and mitochondrial disorders was first established in 1989. In the substantia nigra, and subsequently in peripheral tissues of patients with PD, a 25-35% inhibition of the activity of respiratory chain complex I was detected. The identification of an association between reduced complex I activity and the symptoms of PD left open the question of the role of complex I functional insufficiency in the pathogenesis of Parkinsonism. It should be emphasized that the mechanisms underlying PD remain largely unclear to this day. However, several hypotheses regarding its pathogenesis have been proposed. The resolution of these issues remains highly relevant in both physiology and theoretical and clinical medicine.

Keywords: neurodegenerative disorders; mitochondrial dysfunction; Parkinson's disease; oxidative stress; mitochondrial DNA; gene PINK1; gene PARKIN; gene DG-1; medulla oblongata; striatum; heart; lungs

Full text: (PDF, in Ukrainian)

References

  1. Cehlar O, Njemoga S, Horvath M, Cizmazia E, Bed-narikova Z, Barrera EE. Structures of oligomeric states of tau protein, amyloid-β, α-synuclein and prion protein implicated in Alzheimer's disease, Parkinson's disease and prionopathies. Int J Mol Sci. 2024 Dec 4;25(23):13049. doi: 10.3390/ijms252313049.
  2. Ryu D-W, Han K, Cho A-H. Mortality and causes of death in patients with Parkinson's disease: a nationwide population-based cohort study. Front Neurol. 2023; (14): 1236296. doi: 10.3389/fneur.2023.1236296.
  3. Shapoval LM, Kopyak BS, Dmytrenko OV, Maysky VO, Mankivska OP, Sagach VF. NO-ergic control of circulatory function in the medulla oblongata of rats with experimental hemiparkinsonism under conditions of long-term 24-hour lighting. Physiol. zh. 2016; 62 (6): 50-9. doi:org/10.15407/fz62.06.050. [Ukrainian].
  4. Kozolkin OA, Revenko A V , Medvedklva SO. Parkinson's disease: modern aspects of diagnostics and treatment. Zaporizhzhia: ZDMU; 2017. [Ukrainian].
  5. Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020 Jan;27(1):27-42. doi: 10.1111/ene.14108.
  6. Petrosillo G, Matera M, Casanova G. Mitochondrial dysfunction in rat brain with aging Involvement of complex I, reactive oxygen species and cardiolipin. Neurochem. Int. 2008; 53 (1): 126-31. doi: 10.1016/j. neuint.2008.07.001.
  7. Chekman IS, Belenichev VT, Kolesnyk YM, Gorchakova NO, Bukhtiyarova NV , Morguntsova SA. Pharmacology with the basics of pathology. Zaporizhzhia: ZDMU; 2016. [Ukrainian].
  8. Khaitovich MV. GABA-ergic neuroprotection: clinical application. Med Ukraine. 2016; (1-2): 33-8. [Ukrainian].
  9. Park J-S, Davic RL, Sue CM. Mitochondrial dysfunction in Parkinson's disease: New mechanistic insights and therapeutic perspective. Curr Neurol Neurosci Rep. 2018; 18(5): 21. doi: 10.1007/s11910-018-0829-3.
  10. Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, María Jesús Rey MJ. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Dis. 2014; 29 (8): 1010-8. doi: 10.1002/mds.25776.
  11. Piston D, Alvarez-Erviti L, Bansal V , Gargano D, Yao Z, Szabadkai G, et al. DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis. Hum Mol Genet. 2017; 26 (20): 4028-41. doi: 10.1093/hmg/ ddx294.
  12. Alqahtani T, Deore SL, Kide AA, Shende BA, Sharma R, Роль мітохондріальної дисфункції у розвитку хвороби Паркінсона 91 Dadarao Chakole R, et al. Mitochondrial dysfunction and oxidative stress in Alzheimer's disease, and Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis -an updated review. Mitochondrion. 2023;71:83- 92. doi: 10.1016/j.mito.2023.05.007.
  13. Onyango IG, Khan SM, Bennett JP, Jr. Mitochondria in the pathophysiology of Alzheimer's and Parkinson's diseases. Front Biosci (Landmark Ed). 2017;22(5):854- 72. doi: 10.2741/4521.
  14. Burbulla LF, Song F, Mazzulli JR, Zampese E , Wong YC, Jeon S, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science. 2017; 57 (6357): 1255-61. doi:10.1126/science. aam9080.
  15. Cardoso SM, Oliveira CR. The role of calcineurin in amyloid-betapeptides-mediated cell death. Brain Res. 2005; 1050 (1-2): 1-7. doi:10.1016/j.brainres.2005.04.078.
  16. Mao CX, Wen X, Jin S, Zhang YQ. Increased acetylation of microtubules rescues human tau-induced microtubule defects and neuromuscular junction abnormalities in Drosophila. Dis Model Mech. 2017;10(10):1245-52. doi: 10.1242/dmm.028316.
  17. Ghebremedhin E, Del Tredici K, Langston JW, Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol. 2009; 118 (6): 777-84. doi: 10.1007/ s00401-009-0596-y.
  18. Damiano M, Galvan L, Déglon N, Brouillet E. Mitochondria in Huntington's disease. Biochim Biophys Acta. 2010;1802(1):52-61. doi: 10.1016/j.bbadis.2009.07.012.
  19. Chen X, Yan SD. Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer‘s disea se. IUBMB Life. 2006; 58 (12): 686-94. doi: 10.1080/15216540601047767.
  20. Kramar YA. The role of mitochondrial disorders in the development of mental disorders. NeuroNews. 2017; (4): 30-1. [Ukrainian].
  21. Arteaga O. Role of antioxidants in neonatal hypoxic-ischemic brain injury: New therapeutic approaches. Int J Mol Sci. 2017; 2 (18): 265-87. doi: 10.3390/ ijms18020265.
  22. Armogida M, Spalloni A, Amantea D. The protective role of catalase against cerebral ischemia in vitro and in vivo. Int J Immunopathol Pharmacol. 2011; 24 (3): 735-47. doi: 10.1177/039463201102400320.
  23. Yperzeele L, Shoamanesh A, Venugopalan YV , Chapman S, Mazya MV, Charalambous M, et al. Key design elements of successful acute ischemic stroke treatment trials. Neurol Res Pract. 2023;5(1):1. doi: 10.1186/ s42466-022-00221-9.
  24. Nikonenko AG. Spatial clustering of substantia nigra astrocytes analyzed in rotenone model of hemiparkinsonism. Fiziol Zh. 2022; 68 (5): 10-5. doi: https://doi. org/10.15407/fz68.05.010.
  25. Bernardi P. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J. 2006; 273 (10): 2077-99. doi: 10.1111/j.1742-4658.2006.05213.x.
  26. Denisova MV, N.A. Strutynska NA, L.A. Mys LA, Korkach YuP, Rozova KV , Sagach VF. Mitochondrial dysfunction in acute cardiotoxic effect of doxorubicin in adult rats. Fiziol Zh. 2023; 69 (6): 3-14. doi:org/10.15407/ fz69.06.003. [Ukrainian].
  27. Torres-Gonzalez E, Makova KD. Exploring the effects of mitonuclear interactions on mitochondrial DNA gene expression in humans. Front Genet. 2022;13:797129. doi: 10.3389/fgene.2022.797129.
  28. Kolyada OK, Vaiserman OM, Karaban IM. Genetic basis of Parkinson's disease (review of literature and own research). J Natl Acad Med Sci Ukraine. 2013; 19 (1): 65-74. [Ukrainian].
  29. Chung SJ. Genomic determinants of motor and cog-nitive outcomes in Parkinson's disease. Parkinson Relat Dis. 2012; 10 (2): 257-60. doi:10.1016/j. parkreldis.2012.04.025.
  30. Mazzarini M, Falchi M, Bani D, Migliaccio AR. Evolution fnd new frontiers of histology in bio-medical research. Microsc Res Tech. 2021; 84(2):217-37. doi: 10.1002/ jemt.23579.
  31. Guidelines for the diagnosis and treatment of Parkinson's disease. NeuroNews [Internet]. 2017. Available at: https://neuronews.com.ua/ua/archive/2017/9%2892%29/ pages-33-
  32. 58/rekomendaciyi-shchodo-diagnostiki-ta-likuvannya-hvorobiparkinsona#gsc.tab=0.
  33. McWilliams TG, Barini E, Pohjolan-Pirhonen R, et al. Phosphorylation of Parkin at serine 65 is essential for its activation in vivo. Open Biol. 2018;8(11):180108. doi: 10.1098/rsob.180108.
  34. Paddock C. Scientists confirm the role of ‘molecular switch' in Parkinson's disease. Med News Today, 2018; Nov. 9. Link: www.umj.com.ua/uk/novyna- 133612-molekulyarnye-aspekty-patogeneza-bolezniparkinsona.
  35. Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: much more than mitophagy. Trends Neuro sci. 2014; 37 (6):315-24.
  36. Sarraf SA, Raman M, Guarani-Pereira V , Sowa ME, Hut-tlin EL, Gygi SP , Harper JW. Landscape of the PARKINdependentu biquitylome in response to mitochondrial depolarization. Nature. 2013;496(7445):372.
  37. Park J-S, Davic RL, Sue CM. Mitochondrial dysfunction in Parkinson's disease: New mechanistic insights and therapeutic perspective. Curr Neurol Neurosci Rep. 2018; 18(5): 21. doi: 10.1007/s11910-018-0829-3.
  38. Kolicheski A, Turcano P, Tamvaka N, McLean PJ, Springer W, Savica R, Ross OA. Early-onset Parkinson's disease: Creating the right environment for a genetic disorder. J Parkinson Dis. 2022;12(8):2353-67. doi: 10.3233/ JPD-223380.
  39. Qin P, Sun Y , Li L. Mitochondrial dysfunction in chronic neuroinflammatory diseases (Review). Int J Mol Med. 2024;53(5):47. doi: 10.3892/ijmm.2024.5371.
  40. Bonifati V, Rohé CF, Breedveld GJ. Italian Parkinson К.В. . Розова, Д.С. Красненков, І.М. Карабань 92 Genetics Network. Early-onset Parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology. 2005; 65 (1): 87-95. doi:10.1212/01. wnl.0000167546.39375.82.
  41. Koyano F, Okatsu K, Kosako H, Tamura Y , Go E, Kimura M, et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature. 2014;510(7503):162-6. doi: 10.1038/ nature13392.
  42. Truban D, Hou X, Caulfield TR. PINK1, Parkin, and mitochondrial quality control: what can we learn about Parkinson's disease pathobiology? J Parkinson Dis. 2017; 7 (1), 13-29. doi: 10.3233/JPD-160989.
  43. Rub C, Wilkening A, Voos W. Mitochondrial quality control by the Pink1/Parkin system. Cell Tissue Res. 2017; 367 (1): 111-23. doi: 10.1007/s00441-016-2485-8.
  44. Patten DA, Wong J, Khacho M, Soubannier V , Mailloux R, PilonLarose K, et al. OPA1-dependent cristae modulation is essential for cellular adaptation to metabolic demand. EMBO J. 2014 18; 33(22): 2676-91. doi: 10.15252/ embj.201488349.
  45. Karaban IN. Parkinson`s disease: pathogenetic aspectse drug therapy and clinical course. Int Neurolog J. 2011; 6 (44): 31-38.
  46. Yu D, Pan HX, Zhang RG, Li Y , Nie X. Nucleus DJ-1/ Park7 acts as a favorable prognostic factor and involves mucin secretion in invasive breast carcinoma in Chinese population. Int J Clin Exp Med. 2017; 10(4): 6558-67. doi: 10.1007/s10863-019-09798-4.
  47. Inden M, Kitamura Y, Takahashi K, Takata K, Ito N, Niwa R, et al. Protection against dopaminergic neurodegeneration in Parkinson's disease-model animals by a modulator of the oxidized form of DJ-1, a wildtype of familial Parkinson's disease-linked PARK7. J Pharmacol Sci. 2011; 117(3): 189-203.DOI: 10.1254/ jphs.11151fp.
  48. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM. Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev. 2013;2013:683920. doi: 10.1155/2013/683920.
  49. Xiong N, Long X, Xiong J. Mitochondrial comp-lex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models. Crit Rev Toxicol. 2012; 42(7): 613-32. doi: 10.3109/10408444.2012.680431.
  50. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017; 124(8): 901-5. doi: 10.1007/s00702-017-1686-y.
  51. Maita C, Maita H, Iguchi-Ariga SM, Ariga H. Monomer DJ-1 and its N-terminal sequence are necessary for mitochondrial localization of DJ-1 mutants. PLoS One. 2013;8(1):e54087. doi: 10.1371/journal.pone.0054087.
  52. Rozova К, Putii Y . Is there an organ-specific expression of candidate genes (Dj1, PINK1) in tissues of the organism under experimental parkinsonism and its pathogenetic therapy? Sci Rev. 2021; 1 (36): 31-7. doi: 10.31435/ rsglobal_sr/30012021/7378.
  53. Katunina EA. Antioxidant therapy in the complex treat-ment of Parkinson's disease. [Internet]. 2010. Available at: http://www.pandia.ru/text/77/28/96957.php.
  54. Filograna R, Beltramini M, Bubacco L, Bisaglia M. Anti-oxidants in Parkinson's disease therapy: A critical point of view. Curr Neuropharmacol. 2016; 14(3): 260-71. doi: 10.2174/1570159X13666151030102718.
  55. Shtanova LYa, Vesеlsky SP, Yanchuk PI, Tsymbalyuk OV , et al. Benzodiazepinе derivative methanindiazenone modulates lipid metabolism in the liver of rats with rotenone-induced Parkinson's syndrome. Fiziol Zh. 2023; 69 (6): 77-87.CrossRef
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2026.